Table 1.
Bacterial analysis | Fungal analysis | |||||
---|---|---|---|---|---|---|
Normal | PDAC | p value | Normal | PDAC | p value | |
Cases | 63 | 63 | 43 | 43 | ||
Age (years); mean (range) | 63.6 (41.6 – 79.5) | 65.3 (42.2 – 85.5) | 0.253 | 64.4 (50.4 – 79.5) | 66.3 (50.1 – 84.6) | 0.2624 |
Sex | 0.073 | 0.2424 | ||||
Male (%) | 30 (47.6%) | 40 (63.5%) | 23 (53.5%) | 28 (65.2%) | ||
Female (%) | 33 (52.4%) | 23 (36.5%) | 20 (46.5%) | 18 (34.9%) | ||
Race | 0.76 | 0.6724 | ||||
White (%) | 57 (90.4%) | 57 (90.4%) | 39 (90.7%) | 40 (93.0%) | ||
Non-white (%) | 5 (8.0%) | 4 (6.4%) | 4 (9.3%) | 2 (4.7%) | ||
Missing (%) | 1 (1.6%) | 2 (3.2%) | 0 (0%) | 1 (2.3%) | ||
Smoking status | 0.201 | 0.2483 | ||||
Never smoker (%) | 44 (69.8%) | 36 (57.1%) | 30 (70.0%) | 23 (53.5%) | ||
Former smoker (%) | 18 (28.6%) | 23 (36.5%) | 12 (27.9%) | 17 (39.5%) | ||
Current smoker (%) | 1 (1.6%) | 4 (6.4%) | 1 (2.3%) | 3 (7.0%) | ||
Alcohol consumption | 0.354 | 0.3535 | ||||
Never or occasional (%) | 36 (57.1%) | 36 (57.1%) | 26 (60.5%) | 24 (55.8%) | ||
Regular or heavy (%) | 27 (42.9%) | 25 (39.7%) | 17 (39.5%) | 17 (39.5%) | ||
Missing (%) | 0 (0%) | 2 (3.2%) | 0 (0%) | 2 (4.7%) | ||
Diabetes | <.0001 | 0.0281 | ||||
Yes (%) | 5 (7.9%) | 22 (34.9%) | 6 (14.0%) | 13 (30.2%) | ||
No (%) | 58 (92.1%) | 38 (60.3%) | 37 (86.0%) | 27 (62.8%) | ||
Missing (%) | 0 (0%) | 3 (4.8%) | 0 (0%) | 3 (7.0%) | ||
PPI use | 0.005 | 0.0162 | ||||
Regular (%) | 15 (23.8%) | 34 (54.0%) | 7 (16.3%) | 17 (39.5%) | ||
None (%) | 48 (76.2%) | 29 (46.0%) | 36 (83.7%) | 26 (60.5%) | ||
Probiotics | 0.094 | 0.3145 | ||||
Yes (%) | 1 (1.6%) | 5 (7.9%) | 0 (0%) | 1 (2.3%) | ||
No (%) | 62 (98.4%) | 58 (92.1%) | 43 (100%) | 42 (97.7%) | ||
Antibiotics | 0.171 | 0.5567 | ||||
Yes (%) | 1 (1.6%) | 4 (6.3%) | 1 (2.3%) | 2 (4.6%) | ||
No (%) | 62 (98.4%) | 59 (93.7%) | 42 (97.7%) | 41 (93.4%) | ||
Biliary obstruction | 0 | 11 (17.5%) | 6E-04 | 0 | 8 (18.6%) | 0.0055 |
Tumor location | ||||||
head (%) | 42 (66.7%) | 29 (67.4%) | ||||
body (%) | 15 (23.8%) | 12 (27.9%) | ||||
tail (%) | 6 (9.5%) | 2 (4.7%) | ||||
Tumor Stage | ||||||
IA (%) | 2 (3.2%) | 0 (0%) | ||||
IB (%) | 6 (9.5%) | 2 (4.7%) | ||||
IIA (%) | 9 (14.3%) | 6 (13.9%) | ||||
IIB (%) | 18 (28.6%) | 12 (27.9%) | ||||
III (%) | 9 (14.3%) | 6 (13.9%) | ||||
IV (%) | 19 30.1%) | 17 (39.5%) |